<DOC>
	<DOCNO>NCT01107392</DOCNO>
	<brief_summary>This study evaluate safety efficacy intraprostatic administration botulinum toxin Type A ( BOTOX® ) compare placebo treat urinary tract symptom due benign prostatic hyperplasia .</brief_summary>
	<brief_title>Safety Efficacy Botulinum Toxin Type A Treat Lower Urinary Tract Symptoms Due Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Clinical enlargement prostate gland Body weight ≥ 50 kg 110 lbs History chronic prostatitis History two urinary tract infection past year one last 6 month History bladder stone History previous prostate surgery History bladder cancer prostate cancer Any previous current usage botulinum toxin therapy serotype urological condition Botulinum toxin therapy serotype nonurological condition usage ( e.g. , cosmetic ) previous 12 week prior study entry</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>